The AffloVest is battery-operated and uses Direct Dynamic Oscillation technology, which closely mimics hand CPT (Chest Physical Therapy) to help mobilise and clear secretions from the lungs, and allows for full freedom of mobility during treatment.
Doctors prescribe AffloVest for patients across a range of ages who have severe respiratory diseases such as bronchiectasis, cystic fibrosis, and certain neuromuscular diseases.
This next generation AffloVest, which began shipping September 1, is much lighter, quieter, and more efficient, with a smaller profile battery and long-life, state-of-the-art motors, offering improved patient ease of use.
The new AffloVest is on average 2 pounds lighter (more than 20% less weight) than the previous version, and uses streamlined components and tailored styling for a sleeker, slimmer fit.
International Biophysics brings to market medical devices and technologies aimed at improving treatment therapies and patient outcomes.
The company's precision ISO 13485 certified, FDA registered, quality controlled US manufacturing facility is located in Austin, Texas.
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
Sanofi expedites Beyfortus shipments to support early RSV season readiness
Mediar Therapeutics reports first IPF patient dosed in MTX-463 Phase 2 trial
Innovent's IBI363 granted second breakthrough therapy designation in China
bioMérieux launches rapid PCR test for equine respiratory diseases
BioNTech and Bristol Myers Squibb partner to co-develop bispecific antibody for solid tumours